BioPharma Dive9h
GSK partners with Flagship startup to hunt for Parkinson’s drugs
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
ENDPOINTS NEWS15h
GSK snags Parkin­son's drug from Flag­ship start­up Vesal­ius
GSK has licensed a small molecule for Parkinson's and is teaming up on additional targets for the disease and another ...
FierceBiotech16h
GSK inks Parkinson's pact with Flagship's Vesalius for $570M-plus biobucks
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
GSK’s Trelegy TV ad depicts the reality of living with COPD
GSK’s Trelegy, a treatment for chronic obstructive pulmonary disease (COPD), aimed to address a gap in the market with its ...
FiercePharma18h
GSK, with survey highlighting challenges facing gynecological cancer patients, kicks off initiative to close gaps in care
Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...
Exchange 4 Media23h
TRAI extends dates for submission of comments on Network Authorisations consultation paper
The last dates for submission of written comments and counter-comments on the paper have been extended up to November 19 and November 26, respectively ...